Maxwell Biosciences

Maxwell has a "one drug for many bugs" deep learning-guided drug discovery platform technology which produces small molecules that can accurately mimic endogenous human peptides. The first human peptide being mimicked is LL-37 or "human cathelicidin antimicrobial peptide." LL-37 is used by the human innate immune system and all white blood cells to attack all known pathogens. Accurately and safely mimicking LL-37 could result in a super drug able to address many unmet medical needs, as well as current and future pandemics. The first biomimetic small molecule - MXB-22,510 - is on it's way to the FDA for human trials for a polymicrobial infection of sinus, called Chronic Rhinosinusitis, in Q1 2024. Dr Edward Rudnic, PhD, is a registered pharmacist - is the former US Head of R&D for Shire Pharmaceuticals, recently acquired by Takeda for $65 billion - and has successfully taken over 80 molecules through the FDA and into commercialization. Examples are Adderall XR, Carbatrol, Claritin, and other multi-billion dollar blockbusters.